Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Debt (2017 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Debt for 14 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 15.29% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, down 15.29% year-over-year, with the annual reading at $20.0 million for FY2025, 56.73% up from the prior year.
  • Total Debt for Q4 2025 was $11.9 million at Aytu Biopharma, down from $25.3 million in the prior quarter.
  • The five-year high for Total Debt was $25.3 million in Q3 2025, with the low at $600000.0 in Q1 2021.
  • Average Total Debt over 5 years is $13.7 million, with a median of $14.7 million recorded in 2022.
  • The sharpest move saw Total Debt plummeted 96.55% in 2021, then surged 2277.83% in 2022.
  • Over 5 years, Total Debt stood at $1.3 million in 2021, then surged by 995.36% to $14.6 million in 2022, then increased by 9.44% to $16.0 million in 2023, then fell by 12.55% to $14.0 million in 2024, then dropped by 15.29% to $11.9 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $11.9 million, $25.3 million, and $20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.